Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 3, 2013, Pages 445-452

  Gianotti, Ambra ^a   Melani, Raffaella ^a   Caci, Emanuela ^a   Sondo, Elvira ^a   Ravazzolo, Roberto ^a,b   Galietta, Luis J V ^a   Zegarra Moran, Olga ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Airway surface fluid; CFTR; Cystic fibrosis; ENaC; siRNA

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL SODIUM CHANNEL; SMALL INTERFERING RNA;

ARTICLE; CELL SURFACE; DOWN REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUNG FIBROSIS; RESPIRATORY EPITHELIUM; SODIUM ABSORPTION;

BODY FLUIDS; BRONCHI; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; EPITHELIAL SODIUM CHANNEL BLOCKERS; EPITHELIAL SODIUM CHANNELS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; ION TRANSPORT; MUTATION; PRIMARY CELL CULTURE; RESPIRATORY MUCOSA; RNA, SMALL INTERFERING;

EID: 84883473714     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0408OC     Document Type: Article

References (38)

1. Accurso FJ. Update in cystic fibrosis 2007. Am J Respir Crit Care Med 2008;177:1058-1061. (Pubitemid 351717562)
2. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004;23:146-158. (Pubitemid 38088512)
3. Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, Taft PJ, Rogan MP, Pezzulo AA, Karp PH, Itani OA, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008;321:1837-1841.
4. + absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004;10:487-493.
5. Becq F, Mall MA, Sheppard DN, Conese M, Zegarra-Moran O. Pharmacological therapy for cystic fibrosis: from bench to bedside. J Cyst Fibros 2011;10:S129-S145.
6. Galietta LJV, Springsteel MF, Eda M, Niedzinski EJ, By K, Haddadin MJ, Kurth MJ, Nantz MH, Verkman AS. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001;276:19723-19728.
7. Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran O, Galietta LJ, Verkman AS. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 2002;277:37235-37241.
8. Caci E, Folli C, Zegarra-Moran O, Ma T, Springsteel MF, Sammelson RE, Nantz MH, Kurth MJ, Verkman AS, Galietta LJ. CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. Am J Physiol Lung Cell Mol Physiol 2003;285:L180-L188. (Pubitemid 36736481)
9. Sammelson RE, Ma T, Galietta LJ, Verkman AS, Kurth MJ. 3-(2-benzyloxyphenyl)isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. Bioorg Med Chem Lett 2003;13:2509-2512. (Pubitemid 36830761)
10. Pedemonte N, Diena T, Caci E, Nieddu E, Mazzei M, Ravazzolo R, Zegarra-Moran O, Galietta LJ. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol Pharmacol 2005;68:1736-1746. (Pubitemid 41654357)
11. Pedemonte N, Boido D, Moran O, Giampieri M, Mazzei M, Ravazzolo R, Galietta LJ. Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel. Mol Pharmacol 2007;72:197-207. (Pubitemid 46998539)
12. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-1672.
13. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011;108:18843-18848.
14. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al. Results of a Phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-18.
15. Donaldson SH, Boucher RC. Update on pathogenesis of cystic fibrosis lung disease. Curr Opin Pulm Med 2003;9:486-491. (Pubitemid 37268212)
16. Chen J-H, Stoltz DA, Karp PH, Ernst SE, Pezzulo AA, Moninger TO, Rector MV, Reznikov LR, Launspach JL, Chaloner K, et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 2010;143:911-923.
17. + conductance. Proc Natl Acad Sci USA 2011;108:10260-10265.
18. App EM, King M, Helfesrieder R, Köhler D, Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease: a rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990;141:605-612. (Pubitemid 20109146)
19. Lindemann H, Becker T, Bittner P, Boldt A, Hofmann T, Schwandt HJ. Elimination of secretions in CF patients under amiloride inhalation [in German]. Pneumologie 1990;44:1148-1150. (Pubitemid 20380277)
20. Hofmann T, Senier I, Bittner P, Hüls G, Schwandt HJ, Lindemann H. Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis. J Aerosol Med 1997;10:147-158. (Pubitemid 27265878)
21. Hirsh AJ, Sabater JR, Zamurs A, Smith RT, Paradiso AM, Hopkins S, Abraham WM, Boucher RC. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2004;311:929-938. (Pubitemid 39612697)
22. Hirsh AJ, Zhang J, Zamurs A, Fleegle J, Thelin WR, Caldwell RA, Sabater JR, Abraham WM, Donowitz M, Cha B, et al. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy) phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008;325:77-88. (Pubitemid 351439164)
23. + transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am J Physiol Lung Cell Mol Physiol 2001;281:L16-L23.
24. Coote K, Atherton-Watson HC, Sugar R, Young A, MacKenzie-Beevor A, Gosling M, Bhalay G, Bloomfield G, Dunstan A, Bridges RJ, et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther 2009;329:764-774.
25. Caci E, Melani R, Pedemonte N, Yueksekdag G, Ravazzolo R, Rosenecker J, Galietta LJ, Zegarra-Moran O. Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA. Am J Respir Cell Mol Biol 2009;40:211-216.
26. - currents activated by extracellular nucleotides in human bronchial cells. J Membrane Biol 1997;156:297-305.
27. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-1015. (Pubitemid 29019052)
28. 2 environment on epithelial sodium channel (ENaC) expression in perinatal guinea-pig lung. J Physiol 2000;522:147-157.
29. Harris M, Firsov D, Vuagniaux G, Stutts MJ, Rossier BC. A novel neutrophil elastase inhibitor prevents elastase activation and surface cleavage of the epithelial sodium channel expressed in Xenopus laevis oocytes. J Biol Chem 2007;282:58-64. (Pubitemid 47076633)
30. + channels are fully activated by furin- and prostasin-dependent release of an inhibitory peptide from the gamma-subunit. J Biol Chem 2007;282:6153-6160.
31. Tong Z, Illek B, Bhagwandin VJ, Verghese GM, Caughey GH. Prostasin, a membrane-anchored serine peptidase, regulates sodium currents in JME/CF15 cells, a cystic fibrosis airway epithelial cell line. Am J Physiol Lung Cell Mol Physiol 2004;287:L928-L935. (Pubitemid 39391022)
32. + channel and airway surface liquid volume by serine proteases. Eur J Physiol 2010;460:1-17.
33. Melani R, Galietta LJ, Zegarra Moran O. Analysis of ion transport in the airway epithelium using RNA interference. Curr Opin Mol Ther 2009;11:282-291.
34. 2B adenosine receptors regulate the mucus clearance component of the lung's innate defense system. Am J Respir Cell Mol Biol 2008;39:190-197.
35. Tarran R, Button B, Picher M, Paradiso AM, Ribeiro CM, Lazarowski ER, Zhang L, Collins PL, Pickles RJ, Fredberg JJ, et al . Normal and cystic fibrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections. J Biol Chem 2005;280:35751-35759. (Pubitemid 41532768)
36. Schütze N. siRNA technology. Mol Cell Endocrinol 2004;213:115-119. (Pubitemid 38210044)
37. 2+-activated potassium channels in human airway Calu-3 epithelial cells. Am J Physiol Cell Physiol 2008;294:C1443-C1453.
38. Nielsen EJB, Nielsen JM, Becker D, Karlas A, Prakash H, Glud SZ, Merrison J, Besenbacher F, Meyer TF, Kjems J, et al. Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles. Pharm Res 2010;27:2520-2527.